Literature DB >> 21392524

Revisiting the cholinergic hypothesis in the development of Alzheimer's disease.

Laura A Craig1, Nancy S Hong, Robert J McDonald.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia affecting the elderly population today; however, there is currently no accurate description of the etiology of this devastating disorder. No single factor has been demonstrated as being causative; however, an alternative co-factors theory suggests that the interaction of multiple risk factors is responsible for AD. We have used this model, in combination with the original cholinergic hypothesis of AD to propose a "new" cholinergic hypothesis that we present in this review. This new version takes into account recent findings from the literature and our reports of removal of medial septum cholinergic projections to the hippocampus reduces both behavioural and anatomical plasticity, resulting in greater cognitive impairment in response to secondary insults (stress, injury, disease, etc.). We will first summarize the experimental results and discuss some potential mechanisms that could explain our results. We will then present our 'new' version of the cholinergic hypothesis and how it relates to the field of AD research today. Finally we will discuss some of the implications for treatment that arise from this model and present directions for future study.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392524     DOI: 10.1016/j.neubiorev.2011.03.001

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  90 in total

1.  Cholinergic blockade reduces theta-gamma phase amplitude coupling and speed modulation of theta frequency consistent with behavioral effects on encoding.

Authors:  Ehren L Newman; Shea N Gillet; Jason R Climer; Michael E Hasselmo
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

2.  Neurotrophic factors rescue basal forebrain cholinergic neurons and improve performance on a spatial learning test.

Authors:  Yu-Shang Lee; Andalib Danandeh; Janie Baratta; Ching-Yi Lin; Jen Yu; Richard T Robertson
Journal:  Exp Neurol       Date:  2013-09-07       Impact factor: 5.330

Review 3.  Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.

Authors:  David B Hogan
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

4.  Boosting weakened synapses to treat Alzheimer's disease.

Authors:  Robert J McDonald; Scott H Deibel
Journal:  Learn Behav       Date:  2017-06       Impact factor: 1.986

5.  5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor.

Authors:  Li Wang; Ignacio Moraleda; Isabel Iriepa; Alejandro Romero; Francisco López-Muñoz; Mourad Chioua; Tsutomu Inokuchi; Manuela Bartolini; José Marco-Contelles
Journal:  Medchemcomm       Date:  2017-04-28       Impact factor: 3.597

Review 6.  Estrogen-cholinergic interactions: Implications for cognitive aging.

Authors:  Paul Newhouse; Julie Dumas
Journal:  Horm Behav       Date:  2015-07-14       Impact factor: 3.587

7.  Poly (n-butyl cyanoacrylate) as a nanocarrier for rivastigmine transport across the blood-brain barrier in Alzheimer's disease treatment: a perspective from molecular dynamics simulations.

Authors:  Seyed Vahid Mousavi; Seyed Majid Hashemianzadeh
Journal:  J Mol Model       Date:  2018-08-25       Impact factor: 1.810

Review 8.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

Review 10.  Cerebrovascular reactivity to carbon dioxide in Alzheimer's disease.

Authors:  Lidia Glodzik; Catherine Randall; Henry Rusinek; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.